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Abstract To evaluate the predictive value of vascular endothelial growth factor (VEGF) inthe differential diagnosis of
pleuritis and its associationwith other proinflammatorycytokines inpleural effusion, wemeasured VEGF together with
interleukin-1beta (IL-1b), tumornecrosis factor alpha (TNF-a) and soluble intercellular adhesionmolecule-1 (sICAM-1) in
pleural effusions.We investigated127 patients with pleural effusion (congestive heart failure: 21; parapneumonic: 27; tu-
berculous: 41; malignant: 38).We examined standardparameters of pleural effusion andmeasuredpleural effusionVEGF,
IL-1b,TNF-a and sICAM-1 using enzyme-linked immunosorbent assay.VEGF level was significantly higher in malignant
effusion than in other groups.TNF-a levelwas significantly higher in tuberculous pleurisy than in other groups. In tuber-
culous pleurisy,VEGF level showed significant positive correlationswithmononuclear cell counts and all investigated cy-
tokines.The sensitivity and specificity of VEGF in the diagnosis of malignancy was 100 and 84%, respectively (cutoff =
2000 pg/ml). The sensitivity and specificity of VEGF and TNF-a in the diagnosis of tuberculous pleurisy (VEGF titer
o2000 pg/ml and TNF-a titer455 pg/ml) was 88.9 and 77.1%, respectively.We propose that measurement of VEGF
together withTNF-a is helpful in differentiating between tuberculous pleurisy and malignant pleural effusion and that
VEGF correlateswith proinflammatory cytokines especially in tuberculous pleurisy.We also propose thatmeasurement
of pleural VEGF is helpful for the diagnosis ofmalignantpleural effusion.r2002 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1364, available online athttp://www.idealibrary.comon
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Vascular endothelial growth factor (VEGF), also known
as vascular permeability factor, is a multifunctional cyto-
kine that has recently receivedmuch attention.VEGF ap-
pears to have two primary functions: (1) it increases the
permeability of the vasculature (1), and (2) it is an impor-
tant angiogenic factor especially inmalignant tumors (2).
On the basis of these functions,VEGF has been found to
be associatedwith not onlymalignant neoplasm but also
some chronic in£ammatorydiseases such as tuberculosis
(3,4). In addition,VEGF has associations with some other
cytokines such as soluble intercellular adhesion mole-
cule-1 (sICAM-1) and tumor necrosis factor alpha (TNF-
a) (5,6), which are also found in pleural e¡usions of some
diseases (7F9). In pleural e¡usion, however, little isReceived 9 July 2001, accepted in revised form15 March 2002
Correspondence should be addressed to: Hiroaki Momi,MD,Third
Department of Internal Medicine, Faculty of Medicine, Kagoshima
University, Sakuragaoka 8-35-1,Kagoshima 890-8520, Japan.Fax: 8199
265 7164; E-mail: momimomi@po.synapse.ne.jpknown about the relationship of VEGF levels with diag-
nosis categories and its association with other proin-
£ammatory cytokines. In this study, we hypothesized
that measurement of VEGF together with other proin-
£ammatory cytokines may be helpful in the di¡erential
diagnosis of pleural e¡usion. We therefore measured
VEGF together with interleukin-1 beta (IL-1b), TNF-a
and sICAM-1 in 127 patients with pleural e¡usions. We
found that measurement of pleural VEGF level together
with pleural TNF-a level is helpful in di¡erentiating be-
tween tuberculous pleurisy and malignant pleural e¡u-
sions.
Patients andmethods
This study was reviewedand approvedby theKagoshima
University Faculty of Medicine Committee on Human
Research (Institutional Review Board).We investigated
127 consecutive patients (male: female = 71:56, mean
age = 63.1735.2 years) with pleural e¡usions who were
admitted to theThird Department of Internal Medicine
818 RESPIRATORYMEDICINE(Kagoshima University Faculty of Medicine) from1995 to
2000. Thoracentesis was performed under ultrasound
guidance.
Standard de¢nitions were used for identifying the
cause of the pleural e¡usion (10). A pleural e¡usion
due to congestive heart failure (CHF) was diagnosed if
the patient had symptoms and signs of congestive heart
failure that improved with appropriate therapy. A
parapneumonic e¡usion was an e¡usion associated with
bacterial, viral infection orcollagendiseases.Pleural e¡u-
sion was diagnosed to be tuberculous if the patient
showed growth of Mycobacterium tuberculosis from
pleural £uid or if granulomatous pleuritis was demon-
strated on a closed pleural biopsy specimen and showed
improvement of symptoms and resolution of pleural
e¡usion with anti-tuberculous therapy. The pleural
e¡usion was said to be malignant if the patient had
either a pleural £uid cytologic examination or a
pleural biopsy specimen that were positive for
malignancy.
At the time of thoracentesis, pleural £uid was col-
lectedin a hematology tube for cell count and di¡erential
count, in a tubewith no additive for glucose, protein, lac-
tate dehydrogenase (LDH) and adenosine deaminase
(ADA) analysis and in a tubewithno additive for themea-
surement of cytokines. At the same time, we obtained
10ml venous blood. The pleural £uid for cytokine
measurement and the blood were immediately centri-
fuged at 3000 rpm for 10min at 41. The supernatant of
pleural £uid and blood were separated from the cellular
pellet and was frozen at 251 for further cytokine ana-
lysis.
We measured the cytokines in pleural e¡usion and in
blood using the following enzyme-linked immunosor-
bent assay (ELISA) kits: TNF-a, IL-1b, VEGF (R&D Sys-
tems Co., Minneapolis, MN, USA), and sICAM-1
(BioSource International Inc., Camarillo, CA, USA) ac-
cording to themanufacturer’s protocols.TABLE 1. Characteristics of pleural £uid in di¡erentdiagnostic g
Category CHF
(n=21)
Pne
(n=
Protein (g/dl) 2.370.6 4.87
Glucose (mg/dl) 99.7726.4 94.17
LDH (IU/l) 192.17157.2 991.27
ADA (IU/l) 13.674.6 38.77
TLCcounts (/ml) 299.97163.6 1287.77
PMN counts (/ml) 57.9742.8 184.87
MN counts (/ml) 140.8778.2 728.47
Data are presented asmean7standard deviation,CHF: conge
tate dehydrogenase; ADA: adenosine deaminase;TLC: total leu
cell.STATISTICALANALYSIS
We used one-way factorial ANOVA with Bonnferroni/
Dunn test to evaluate the di¡erence of the parameters
between each group (P value below 0.0083 was consid-
ered signi¢cant).We also employed Pearson’s correlation
coe⁄cient to see the correlation of VEGF with each
parameter (P value below 0.05 was considered signi¢-
cant). We used the Mann^Whitney U test to evaluate
the di¡erence of cytokine levels in serum and pleural ef-
fusion (P value below 0.05 was considered signi¢cant).
Most values were expressed as mean7standard devia-
tions (SD).
RESULTS
The diagnosis and the pleural £uid characteristics of the
127 patients are shown inTable1.Twenty-onepatientshad
pleural e¡usion due to CHF, 27 had parapneumonic e¡u-
sion (21withbacterial infection, 3with viral infection and
3 with bronchiectasis), 41were diagnosed to have tuber-
culous pleurisy and 38 had malignant e¡usion. All malig-
nant pleural e¡usions were associated with lung cancer
(non-small cell lung cancer: 32; small cell lung cancer: 6).
Protein levels, LDHlevels andmononuclear cell counts in
CHF e¡usion were signi¢cantly lower than other e¡u-
sions (Po0.0083). ADA level in tuberculous pleural e¡u-
sion was signi¢cantly higher than in CHF e¡usion and
malignant pleural e¡usion (Po0.0083); however, the dif-
ference between tuberculous pleural e¡usion and para-
pneumonic e¡usion was not signi¢cant (P=0.029). Total
cell count in CHF e¡usion was signi¢cantly lower than
tuberculous and parapneumonic e¡usions (Po0.0083).
Glucose level and polymorphonuclear cell counts
showed no signi¢cant di¡erence in each group.
The cytokine levels in pleural £uid and in blood are
shown inTable 2.VEGF level inmalignant e¡usionwas sig-
ni¢cantly higher than in other groups [Fig. 1(A)]. TNF-aroups
um
27)
Tuberculous
(n=41)
Malignant
(n=38)
0.7 4.770.8 4.870.8
36.9 101.5724.8 91.8739.6
579.9 963.27600.8 1309.471101.7
34.9 48.9725.9 28.1717.7
1078.3 1370.27999.4 885.57755.9
282.1 116.27179.9 85.3734.4
587.6 9967808.6 672.57657.5
stive heart failure;Pneum: parapneumonic e¡usion;LDH: lac-
kocyte cell; PMN: polymorphonuclear cell; MN: mononuclear
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in other groups [Fig.1(B)]. IL-1b and sICAM-1showed no
signi¢cant di¡erence between parapneumonic, tubercu-
lous andmalignant e¡usions [Fig.1(C) and (D)]. All cyto-
kine levels in CHF e¡usion were signi¢cantly lower than
in other groups.VEGF levels in the blood of patientswith
malignant pleural e¡usion were signi¢cantly higher than
in other groups (Po0.0083). All cytokine levels in the
blood of CHF patients were signi¢cantly lower than in
other groups. TNF-a, IL-1b and sICAM-1 levels in the
blood showed no signi¢cant di¡erence between para-
pneumonic, tuberculous and malignant e¡usions. In pa-
tients with parapneumonic, tuberculous and malignant
e¡usions,TNF-a andVEGF levels in pleural £uidwere sig-
ni¢cantly higher than in blood. In the patients with para-
pneumoic pleural e¡usion, IL-1b level was signi¢cantly
higher in pleural £uid than in blood.With regard to sI-
CAM-1, there was no signi¢cant di¡erence between
pleural £uid and blood levels in all patients examined.
The sensitivity and speci¢city for the diagnosis of ma-
lignancy using VEGF level in pleural e¡usion was100 and
84%, respectively (cuto¡ = 2000pg/ml). The sensitivity
and speci¢city for the diagnosis of tuberculous pleurisy
usingTNF-a level in pleural e¡usion was 69.6 and 75.9%,
respectively (cuto¡= 55pg/ml).The sensitivity and speci-
¢city for the diagnosis of tuberculous pleurisy using
VEGF and TNF-a levels in pleural e¡usion (VEGF titer
o 2000pg/ml and TNF-a titer455pg/ml) was 88.9 and
77.1%, respectively.The sensitivity and speci¢city for the
diagnosis of tuberculous pleurisy using ADA level in
pleural e¡usion was 64.1 and 81.1% (cut o¡ = 40 IU/l), re-
spectively.
Table 3 shows the results of the statistical correlation
of VEGF with parameters of pleural e¡usion or proin-
£ammatory cytokines in each group. In CHF patients,
VEGF showed no signi¢cant correlation with the para-
meters or cytokines. In patients with parapneumonic ef-TABLE 2. Comparison of cytokine levels betweenpleural £uid
Category CHF
(n=21)
Pneum
(n=27)
Pleural £uid
VEGF (pg/ml) 20.5711.5 402.67241
TNF-a¤ (pg/ml) 2.172.1 28.1725.1
IL-1a“ (pg/ml) 7.777.6 163.87118.
sICAM-1 (pg/ml) 16.2711.9 163.57105
Blood
VEGF (pg/ml) 24.5716.6 259.97234
TNF-a¤ (pg/ml) 1.571.9 4.372.9
IL-1a“ (pg/ml) 6.374.3 118.8796.
sICAM-1 (pg/ml) 16.479.9 132.4794.7
Data are presented asmean7standard deviation;CHF: conge
*Po0.01, **Po0.001, comparisonbetweenpleural £uid level andfusion,VEGF showed signi¢cant positive correlationwith
LDH, IL-1b and sICAM-1. In tuberculous e¡usion, VEGF
level showed signi¢cantpositive correlationswithmono-
nuclear cell counts, LDH, ADA, IL-1b,TNF-a and sICAM-
1levels, however, inmalignant e¡usion, it showed signi¢-
cant positive correlation only with LDH and sICAM-1
levels.
DISCUSSION
Pleural e¡usion is a commonclinical problem, but thede-
tailed pathogenesis of pleural £uid accumulation remains
poorly understood. In malignant pleural e¡usion, VEGF
has been said to be associatedwith pleural £uid accumu-
lation; however, the association of VEGFwith proin£am-
maory cytokines and the origin of VEGF is still
controversial (11). In our study, pleural VEGF levels inma-
lignant e¡usion were considerably higher than in other
groups. This result suggests that VEGF should be used
as one of the markers for malignant pleural e¡usions.
Pleural VEGF showed no signi¢cant association with cell
counts inpleural e¡usion; however, the serumVEGF level
ofpatientswithmalignantpleural e¡usionwas extremely
higher than other groups as was seen in pleural £uid re-
sults. This result may suggest that the origin of pleural
VEGF in malignant pleural e¡usion is not in¢ltrating
mononuclear cells.We think that the origin of VEGF in
malignant pleural £uid may be mesothelial cells and/or
malignant cells in the pleural space for the following rea-
sons: (1) Mesothelial cells which line the pleural space
have been demonstrated to produce large quantities of
VEGF (12). (2) Production of VEGF by pleural macro-
phages did not correlate with pleural VEGF levels in ma-
lignant pleural e¡usions (13). Malignant cells themselves
may produce VEGF resulting in transmigration docking
and growth on the pleural surface. Yano et al. (14)and sera in each group
Tuberculous
(n=41)
Malignant
(n=38)
.6** 810.37543.6* 2006.871304.8**
** 46.9734.3** 28.9724.1**
9** 156.17114.8 178.27183.4
.5 172.57127.9 210.17203.2
.1 553.97306.7 1190.77729.3
6.973.7 5.975.1
2 160.87100.2 169.87128.9
189.97154.1 163.27145.2
stive heart failure;Pneum: parapneumonic e¡usion.
blood level in each group.
FIG. 1. Comparisonofpleuralcytokinelevelsbetween 4 groups (A:VEGF,B:TNF-a,C:IL-1b;D: sICAM-1). *Po0.0001comparedwith
each cytokine level in pleural e¡usion of CHF patients.Bars show themean values.CHF: congestive heart failure; Pneum: parapneu-
monic pleural e¡usion.
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malignant e¡usions in vitro.VEGF may also play an impor-
tant role in the transmigration of malignant cells from
the vascular compartment into the pleural space.
In our study,VEGF titers in malignant pleural e¡usion
showed a signi¢cant positive correlation only with sI-
CAM-1 (Table 3). ICAM-1 acts as a ligand for b2 leuko-
cyte integrin (15) and is thought to stabilize the
adhesion of leukocytes to the endothelium (16). The
ICAM-1 that is shed from the cell surface can be de-
tected as sICAM-1. VEGF can induce the expression of
ICAM-1 on endothelial cells (5). We think this may be
the reason why only the sICAM-1 titer of malignant
pleural e¡usion showed a signi¢cant positive correlation
with pleural VEGF levels. In agreementwith previous re-
ports, we think that VEGF in malignant pleural e¡usion
may contribute to £uid accumulation in combinationwith ICAM-1because of the following reasons: (1) VEGF
is a selective endothelial mitogen and is 10 000 times
more potent than histamine in enhancing vascular per-
meability (17), (2) ICAM-1 plays a critical role in cellular
tra⁄cking of leukocytes from thevascular compartment
to the pleural space (18).
In tuberculous pleurisy, pleural VEGF level showed sig-
ni¢cantpositive correlationwithmononuclear cell count
and all investigated cytokines. In tuberculosis, TNF-a
contributes to the activation ofmonocytes/macrophages
(19) and stimulates chemotactic factors such as IL-1bthat
attract in£ammatory cells into the lesion (20).TNF-a can
up-regulate the expression of VEGF (6). ICAM-1 is also
associated with monocyte transmigration during tuber-
culous pleural in£ammation (21). Therefore, we think
that pleural VEGF level can re£ect the activity of
tuberculous pleurisy. Although we could not deny the
FIG. 1. (Continued).
TABLE 3. Correlation betweenVEGF and parameters of pleural e¡usion or proin£ammaotry cytokines in tuberculous and
malignante¡usions
Whole
(n=127)
CHF
(n=21)
Pneum.
(n=27)
Tuberculous
(n=41)
Malignant
(n=38)
MN count r=0.167 r=0.102 r=0.334 r=0.838w r=0.219
PMN count r=0.052 r=0.121 r=0.191 r=0.164 r=0.322
Protein r=0.125 r=0.153 r=0.211 r=0.189 r=0.113
LDH r=0.533w r=0.299 r=0.398* r=0.965w r=0.354*
Glucose r=0.062 r=0.087 r=-0.091 r=0.099 r=0.223
ADA r=0.189 r=0.024 r=0.266 r=0.398** r=0.131
TNF-a r=0.25** r=0.19 r=0.391 r=0.818w r=0.321
IL-1b r=0.328*** r=0.132 r=0.398** r=0.533*** r=0.164
sICAM-1 r=0.532w r=0.231 r=0.422** r=0.471** r=0.529***
MN: mononuclear cell,PMN: polymorphonuclear cell,LDH: lactate dehydrogenase.
*Po0.05, **Po0.01, ***Po0.001, wPo0.0001.
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822 RESPIRATORYMEDICINEpossibility of being transported from sera, we think that
the origin of VEGF in tuberculous pleurisy is probably the
mononuclear cells in the pleural £uid.We propose that
pleural VEGF level may become one of the useful mar-
kers to predict the activity of tuberculous pleurisy.
In parapneumonic pleural e¡usion, pleural VEGF level
showed signi¢cant correlations with only two investi-
gated cytokines and did not correlate with cell counts
signi¢cantly. Pleural mesothelial cells can produce some
cytokines including VEGF and ICAM (12,18).The correla-
tion of VEGFwith proin£ammatory cytokinesmayrelate
to the increased activityof thepleuralmesothelial cells in
in£ammatory pleural disease.
Our results also showed the high sensitivity of VEGF
for diagnosingmalignantpleural e¡usion and its relatively
high sensitivity and speci¢city for diagnosing tuberculous
pleurisy when used in combination withTNF-a. In addi-
tion, the sensitivity for using VEGF in combination with
TNF-a for the diagnosis of tuberculouspleurisy washigh-
er than when using ADA alone. We suggest that mea-
surement of VEGF in combination with TNF-a might
become one of the useful screening markers for the dif-
ferential diagnosis of pleural e¡usion. Our study is too
small to draw any de¢nitive conclusion. Further studies
addressing this point are necessary to clarify the signi¢-
cance of VEGF in pleural e¡usion.
Acknowledgements
Wewould like to give special thanks to Kenichi Ohnaka-
hara (MD) (Department of Respiratory Medicine, Na-
tional Minami-kyushu Hospital) and Takayuki Suetsugu
(MD) (Department of Internal Medicine, Kagoshima
Kenritsu Hokusatsu Hospital) for their advice on this
study.We also give special thanks to Mrs Rumi Matsuya-
ma (Third Department of Internal Medicine, School of
Medicine Kagoshima University) for her excellent assis-
tance with this study. We also appreciate the language
editing of Dr Arlene R.Ng (Third Department of Inter-
nal Medicine, School of Medicine Kagoshima University).
REFERENCES
1. Brown LF, Detmar M, Claffey K, etal. Vascular permeability factor/
vascular endothelial growth factor: a multifunctional angiogenic
cytokine. EXS 1997; 79: 233–269.
2. Donovan D, Harmey JH, Toomey D, Osborne DH, Redmond HP,
Bouchier-Hayes DJ. TGF beta-1 regulation of VEGF production by
breast cancer cells. Ann Surg Oncol 1997; 4: 621–627.
3. Mattern J, Koomagi R, Volm M. Coexpression of VEGF and bFGF
in human epidermoid lung carcinoma is associated with increased
vessel density. Anticancer Res 1997; 17: 2249–2252.4. Matsuyama W, Hashiguchi T, Matsumuro K, etal. Increased serum
level of vascular endothelial growth factor in pulmonary
tuberculosis. Am J Respir Crit Care Med 2000; 162: 1120–1122.
5. Kim I, Moon SO, Hoon Kim S, Jin Kim H, Soon Koh Y, Young Koh
G. Vascular endothelial growth factor expression of intercellular
adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1
(VCAM-1), and E-selectin through nuclear factor-kappa B activa-
tion in endothelial cells. J Biol Chem 2001; 276: 7614–7620.
6. Ryuto M, Ono M, Izumi H, et al. Induction of vascular endothelial
growth factor by tumor necrosis factor a in human glioma cells. J
Biol Chem 1996; 271: 28 220–28 228.
7. Hua CC, Chang LC, Chen YC, Chang SC. Proinflammatory
cytokines and fibrinolystic enzymes in tuberculous and malignant
pleural effusions. Chest 1999; 116: 1292–1296.
8. Orphanidou D, Gaga M, Rasidakis A, etal. Tumor necrosis factor,
interleukin-1 and adenosine deaminase in tuberculous pleural
effusion. Respir Med 1996; 90: 95–98.
9. Hoffmann JC, Kruger H, Luhrs J, Hamm H. Detection of soluble
adhesion molecules in pleural effusions. Chest 1996; 110: 107–113.
10. Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr. Pleural
effusions: the diagnostic separation of transudates and exudates.
Ann Intern Med 1972; 77: 507–513.
11. Cheng DS, Lee CG, Rogers JT, et al. Vascular endothelial growth
factor level with transforming growth factor-b isoforms levels in
pleural effusions. Chest 2000; 118: 1747–1753.
12. Mohammed KA, Nasreen N, Hardwick J, Logie CS, Patterson CE,
Antony VB. Bacterial induction of pleural mesothelial monolayer
barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 2001, 281:
119–125.
13. Yanagawa H, Takeuchi E, Suzuki Y, Ohmoto Y, Bando H, Sone S.
Vascular endothelial growth factor in malignant pleural effusion
associated with lung cancer. Cancer Immunol Immunother 1999; 48:
396–400.
14. Yano S, Shinohara H, Herbst RS, etal. Production of experimental
malignant pleural effusions is dependent on invasion of the pleura
and expression of vascular endothelial growth factor/vascular
permeability factor by human lung cancer cells. Am J Pathol 2000;
157: 1893–1903.
15. De Gaetano G, Cerletti C, Evangelista V. Recent advances in
platelet–polymorphonuclear leukocyte interaction. Haemostasis
1999; 29: 41–49.
16. Sriramarao P, languino LR, Altieri DC. Fibrinogen mediates
leukocyte–endothelium bridging in vivo at low shear forces. Blood
1996; 88: 3416–3423.
17. Ferrara N, Keyt B. Vascular endothelial growth factor: basic
biology and clinical implications. EXS 1997; 79: 209–232.
18. Mutti L, Piacenza A, Valenti V, Gastagneto B, Betta PG. Expression
of intercellular adhesion molecule-1 (ICAM-1) by reactive
mesothelial cells in pleural effusions. Pathologica 1993; 85: 725–
758.
19. Hirsch CS, Ellner JJ, Russell DG, Rich EA. Complement receptor-
mediated uptake and tumor necrosis factor-alpha-mediated
growth inhibition of Mycobacteriumtuberculosis by human alveolar
macrophages. J Immunol 1994; 152: 743–753.
20. Le J, Vilcek J. Tumor necrosis factor and interleukin 1: cytokines
with multiple overlapping biological activities. Lab Invest 1987; 56:
234–248.
21. Nasreen N, Mohammed KA, Ward MJ, Antony VB. Mycobacter-
ium-induced transmesothelial migration of monocytes into pleural
space: role of intercellular adhesion molecule-1 in tuberculous
pleurisy. J Infect Dis 1999; 180: 1616–1623.
